PDCD1 and head and neck cancer: Additionally, there are weak recommendations to offer PD-1 inhibitors to patients with recurrent or metastatic nasopharyngeal cancer, patients with recurrent or rare head and neck cancers with high TMB, and patients with PD-L1-positive recurrent or metastatic salivary gland cancer [88].